
## Elena Matsa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11671900/publications.pdf Version: 2024-02-01



FLENA MATSA

#	Article	IF	CITATIONS
1	Chemically defined generation of human cardiomyocytes. Nature Methods, 2014, 11, 855-860.	9.0	1,320
2	Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nature Medicine, 2016, 22, 547-556.	15.2	573
3	Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. European Heart Journal, 2011, 32, 952-962.	1.0	363
4	High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Science Translational Medicine, 2017, 9, .	5.8	297
5	Human Stem Cells for Modeling Heart Disease and for Drug Discovery. Science Translational Medicine, 2014, 6, 239ps6.	5.8	175
6	Epigenetic Regulation of Phosphodiesterases 2A and 3A Underlies Compromised β-Adrenergic Signaling in an iPSC Model of Dilated Cardiomyopathy. Cell Stem Cell, 2015, 17, 89-100.	5.2	170
7	Induced pluripotent stem cells: at the heart of cardiovascular precision medicine. Nature Reviews Cardiology, 2016, 13, 333-349.	6.1	152
8	Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes as an In Vitro Model for Coxsackievirus B3–Induced Myocarditis and Antiviral Drug Screening Platform. Circulation Research, 2014, 115, 556-566.	2.0	134
9	Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses InÂVitro. Cell Stem Cell, 2016, 19, 311-325.	5.2	131
10	Passive Stretch Induces Structural and Functional Maturation of Engineered Heart Muscle as Predicted by Computational Modeling. Stem Cells, 2018, 36, 265-277.	1.4	111
11	Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes. European Heart Journal, 2014, 35, 1078-1087.	1.0	107
12	Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine. Physiological Reviews, 2016, 96, 1093-1126.	13.1	93
13	Current status of drug screening and disease modelling in human pluripotent stem cells. BioEssays, 2013, 35, 281-298.	1.2	89
14	Feeder-free culture of human embryonic stem cells in conditioned medium for efficient genetic modification. Nature Protocols, 2008, 3, 1435-1443.	5.5	73
15	A Comprehensive TALEN-Based Knockout Library for Generating Human-Induced Pluripotent Stem Cell–Based Models for Cardiovascular Diseases. Circulation Research, 2017, 120, 1561-1571.	2.0	56
16	Cardiac Stem Cell Biology. Circulation Research, 2014, 114, 21-27.	2.0	54
17	Accurate nanoelectrode recording of human pluripotent stem cell-derived cardiomyocytes for assaying drugs and modeling disease. Microsystems and Nanoengineering, 2017, 3, 16080.	3.4	49
18	Aberrant α-Adrenergic Hypertrophic Response in Cardiomyocytes from Human Induced Pluripotent Cells. Stem Cell Reports, 2014, 3, 905-914.	2.3	46

Elena Matsa

#	Article	IF	CITATIONS
19	Modeling Cardiovascular Diseases with Patient-Specific Human Pluripotent Stem Cell-Derived Cardiomyocytes. Methods in Molecular Biology, 2015, 1353, 119-130.	0.4	35
20	Alloimmune Responses of Humanized Mice to Human Pluripotent Stem Cell Therapeutics. Cell Reports, 2017, 20, 1978-1990.	2.9	31
21	Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes asÂaÂModel to Study Trypanosoma cruzi Infection. Stem Cell Reports, 2019, 12, 1232-1241.	2.3	29
22	Faster generation of hiPSCs by coupling high-titer lentivirus and column-based positive selection. Nature Protocols, 2011, 6, 701-714.	5.5	24
23	In Vitro Uses of Human Pluripotent Stem Cell-Derived Cardiomyocytes. Journal of Cardiovascular Translational Research, 2012, 5, 581-592.	1.1	23
24	Two new protocols to enhance the production and isolation of human induced pluripotent stem cell lines. Stem Cell Research, 2011, 6, 158-167.	0.3	22
25	INSPIRE: A European training network to foster research and training in cardiovascular safety pharmacology. Journal of Pharmacological and Toxicological Methods, 2020, 105, 106889.	0.3	4
26	Alternative approaches to generating cardiomyocytes are under development. Nature Reviews Cardiology, 2016, 13, 574-574.	6.1	1
27	Cardiomyopathy. , 2016, , 11-26.		0